Semaglutide and the Retina

Affiliations

Editorial

Zachary T Bloomgarden. J Diabetes. 2025 Apr.

. 2025 Apr;17(4):e70085.

doi: 10.1111/1753-0407.70085.

¹ Division of Endocrinology, Diabetes and Bone Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

No abstract available

Keywords: diabetes; glucagon‐like peptide‐1 receptor agonists; retinopathy.

Conflict of interest statement

The author declares no conflicts of interest.

1. Teo Z. L., Tham Y. C., Yu M., et al., “Global Prevalence of Diabetic Retinopathy and Projection of Burden Through 2045: Systematic Review and Meta‐Analysis,” Ophthalmology 128, no. 11 (2021): 1580–1591. - PubMed
1. King A., Tan X., Dhopeshwarkar N., et al., “Recent Trends in GLP‐1 RA and SGLT2i Use Among People With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease in the USA,” BMJ Open Diabetes Research & Care 12, no. 5 (2024): e004431. - PMC - PubMed
1. Montero A., Sparks G., Presiado M., and Hamel L., “KFF Health Tracking Poll May 2024: The Public's Use and Views of GLP‐1 Drugs,” 2025, https://www.kff.org/health‐costs/poll‐finding/kff‐health‐tracking‐poll‐m....
1. Kunutsor S. K., Balasubramanian V. G., Zaccardi F., et al., “Glycaemic Control and Macrovascular and Microvascular Outcomes. A Systematic Review and Meta‐Analysis of Trials Investigating Intensive Glucose‐Lowering Strategies in People With Type 2 Diabetes,” Diabetes, Obesity & Metabolism 26, no. 6 (2024): 2069–2081. - PubMed
1. Bloomgarden Z., “Is Insulin the Preferred Treatment for HbA1c >9%?,” Journal of Diabetes 9, no. 9 (2017): 814–816. - PubMed